Buscar
Erasca Inc
ERASAñadir a la lista de seguimiento
18.150USD
-0.530-2.84%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
5.16BCap. mercado
PérdidaP/E TTM
Más Datos de Erasca Inc Compañía
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Información de Erasca Inc
Símbolo de cotizaciónERAS
Nombre de la empresaErasca Inc
Fecha de salida a bolsaJul 15, 2021
Director ejecutivoLim (Jonathan E)
Número de empleados103
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 15
Dirección3115 Merryfield Row
CiudadSAN DIEGO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal92121
Teléfono18584656511
Sitio Webhttps://www.erasca.com/
Símbolo de cotizaciónERAS
Fecha de salida a bolsaJul 15, 2021
Director ejecutivoLim (Jonathan E)
Ejecutivos de Erasca Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
19.46M
--
Mr. Alexander W. (Alex) Casdin
Mr. Alexander W. (Alex) Casdin
Independent Director
Independent Director
667.72K
--
Dr. James Arthur Bristol
Dr. James Arthur Bristol
Lead Independent Director
Lead Independent Director
207.50K
--
Mr. Ebun S. Garner, J.D.
Mr. Ebun S. Garner, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
25.08K
--
Dr. David M. Chacko, M.D.
Dr. David M. Chacko, M.D.
Chief Financial Officer and Chief Business Officer
Chief Financial Officer and Chief Business Officer
--
--
Dr. Julie Hambleton, M.D.
Dr. Julie Hambleton, M.D.
Independent Director
Independent Director
--
--
Dr. Valerie Harding-Start, Ph.D.
Dr. Valerie Harding-Start, Ph.D.
Independent Director
Independent Director
--
--
Dr. Pratik S. Multani, M.D.
Dr. Pratik S. Multani, M.D.
Independent Director
Independent Director
--
--
Dr. Michael David Varney, Ph.D.
Dr. Michael David Varney, Ph.D.
Director, Chair of Research and Development and Scientific Advisory Board member
Director, Chair of Research and Development and Scientific Advisory Board member
--
--
Dr. Jean I. Liu, J.D.
Dr. Jean I. Liu, J.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
19.46M
--
Mr. Alexander W. (Alex) Casdin
Mr. Alexander W. (Alex) Casdin
Independent Director
Independent Director
667.72K
--
Dr. James Arthur Bristol
Dr. James Arthur Bristol
Lead Independent Director
Lead Independent Director
207.50K
--
Mr. Ebun S. Garner, J.D.
Mr. Ebun S. Garner, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
25.08K
--
Dr. David M. Chacko, M.D.
Dr. David M. Chacko, M.D.
Chief Financial Officer and Chief Business Officer
Chief Financial Officer and Chief Business Officer
--
--
Dr. Julie Hambleton, M.D.
Dr. Julie Hambleton, M.D.
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Erasca Inc?
Los cinco principales accionistas de Erasca Inc son: Dr. Jonathan E. Lim, M.D.
¿Cuántas instituciones poseen acciones de Erasca Inc (ERAS)?
A fecha de 2026Q1, 333 instituciones poseen acciones de Erasca Inc, con un valor de mercado combinado de aproximadamente 240.06M, lo que representa el 77.62% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -10457676.00.